sorafenib + carboplatin + paclitaxel

Sorafenib + carboplatin + paclitaxel is a combination regimen used primarily in oncology clinical trials, especially for advanced melanoma and other solid tumors. Sorafenib is an oral multikinase inhibitor that targets several protein kinases involved in tumor cell proliferation and angiogenesis, including vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), and RAF kinases. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis, while paclitaxel stabilizes microtubules to inhibit cell division. This combination has been studied for its potential to improve outcomes over chemotherapy alone; however, large phase III studies have not shown significant improvement in progression-free or overall survival compared to standard chemotherapy regimens[2][3][5]. The addition of sorafenib may increase certain toxicities such as dermatologic events, thrombocytopenia, diarrhea, and fatigue[2]. The use of this regimen is contraindicated in patients with squamous cell lung cancer due to increased mortality risk[8].

Brand names

Nexavar

Other names

CPS